1. Introduction {#sec0001}
===============

Although Parkinson\'s disease is often conceived of as a homogenous disease, there are in fact radical differences in clinical manifestations and progression between patients ([@bib0001]). With this in mind, there is a growing need for identifying biomarkers to predict the progression of PD.

Despite several investigations, discovery of an accurate biomarker for PD progression has been still elusive. Neuroimaging research advances over the past decades, however, have provided promising detailed knowledge of the brain pathology in several neurodegenerative disorders including PD ([@bib0002], [@bib0003]). In particular, Diffusion Tensor Imaging (DTI) has shown various structural abnormalities in PD patients compared to healthy controls. Microstructural damage of white matter integrity, in terms of decreased fractional anisotropy (FA) and increased mean diffusivity (MD) has been reported in several brain regions in PD ([@bib0004], [@bib0005]). Combining DTI analysis with graph theory and further reconstruction of the brain networks has demonstrated disruption of the brain connectivity and widespread pattern of decreased efficiency in PD patients compared to healthy controls ([@bib0006], [@bib0007]). Surprisingly, DTI-based imaging analysis has also succeeded in detecting early pathological brain changes of PD ([@bib0008]). Insufficiency of global neural connections has been recently reported in early stage de novo PD patients, by applying the graph theoretical analysis on DTI scans ([@bib0009]). Moreover, several DTI studies detected an abnormal pattern of PD subnetworks with reduced connectivity using the network-based statistic (NBS) ([@bib0010]), which primarily involved key components of the limbic system, basal ganglia and sensorimotor area ([@bib0011]).

In addition to baseline DTI findings, a 6-year longitudinal study demonstrated increased mean diffusivity in various brain regions and a positive correlation between increased diffusivity in the anterior putamen and PD motor progression ([@bib0012]).

Although few longitudinal investigations have been conducted, systematic longitudinal studies on comprehensive assessments of PD outcomes are still lacking. Considering the alterations of the diffusion properties and damage of white matter tracts, here we primarily aimed to explore whether DTI biomarkers and in particular, structural network properties at baseline, are associated with long-term motor and non-motor outcomes in patients with PD who were enrolled in the Parkinson\'s Progression Markers Initiative (PPMI) cohort ([www.ppmi-info.org/data](http://www.ppmi-info.org/data){#interref0001}). In addition, we investigated if baseline DTI measures are able to distinct clinical subtypes of PD ([@bib0013]).

2. Methods {#sec0002}
==========

2.1. Participants {#sec0003}
-----------------

Participants of the current study were included from the PPMI cohort ([@bib0014]). The PPMI is an ongoing multicenter study consisting of clinical, genetic, biological and imaging measurements of more than 400 PD patients, designed with the goal of identifying disease biomarkers. Each participating PPMI site received approval from a local research ethics committee before study initiation and written informed consent forms were obtained from all subjects participating in the study. According to the inclusion criteria, de novo PD patients aged 30 years or older at the time of diagnosis with at least two of the following clinical features were eligible: resting tremor, bradykinesia, rigidity OR either asymmetric resting tremor or asymmetric bradykinesia. Additional inclusion criteria were a diagnosis of PD for 2 years or less at the time of screening; Hoehn and Yahr stage I or II at the baseline visit; confirmation of dopamine transporter deficit in neuroimaging assessments; and not expected to require PD medications within at least 6 months from the baseline visit. Patients with a history of PD medication use including levodopa, dopamine agonists, MAO-B inhibitors (e.g., selegiline, rasagiline), amantadine or other PD medications within 60 days of the baseline visit or having a clinical diagnosis of dementia -as determined by the investigator on the basis of the criteria developed by the Movement Disorders Society (MDS)- were excluded ([@bib0014]).

2.2. Clinical subtypes {#sec0004}
----------------------

We recently recommended guidelines for subtyping de novo PD subjects based on clinical features ([@bib0013]). Three distinct subtypes of PD were defined by hierarchical clustering based on a composite motor severity score and three main non-motor domains at baseline: REM sleep behavior disorder (RBD), dysautonomia, and cognitive impairment. The "mild motor-predominant" subtype consists of individuals with both composite motor and all non-motor symptom scores below the 75th percentile of severity (calculated from the same PPMI population). At the other end of the spectrum, two criteria categorized the "diffuse-malignant" subtype: individuals who scored \>75th percentile in composite motor symptom score and at least one of the three non-motor domains or those who scored \>75th percentile in all three non-motor domains, regardless of the motor severity. The remaining cases were classified as the "intermediate" subtype. This classification was supported by differing rates of progression of clinical and structural imaging measures at 2.7 years. To investigate if baseline DTI analysis could predict shifting in clinical subtypes, we reclassified participants after 4.5 years of follow-up by using the updated reference percentile values derived from the score distribution of these motor and non-motor features.

Applying this comprehensive classification on PPMI participants, 422 PD subjects were subcategorized into one of three subtypes, mild-motor predominant, intermediate and diffuse-malignant. Among them, 152 patients had undergone DTI scan of the brain at the baseline visit. The scans underwent a basic quality control assessment by the Center for Imaging of Neurodegenerative Diseases (VA Medical Center, San Francisco, CA), and processed images were uploaded to the PPMI website. We also checked each scan visually for quality assessment. Thereafter, 8 participants that either had only one baseline DTI or failed the quality control were excluded from our study, so that 144 PD patients (82 mild-motor predominant, 48 intermediate and 14 diffuse-malignant on baseline classification) were included for the main analysis.

2.3. Clinical measures {#sec0005}
----------------------

A comprehensive set of demographic and clinical features were recorded at enrollment and at every follow-up visit for each participant. [Table 1](#tbl0001){ref-type="table"} summarizes the baseline and 4.5-year follow-up values for each clinical measure categorized into motor and non-motor manifestations.Table 1Demographic and clinical characteristics of the study population (*n* = 144) at baseline and the end of follow-up (4.5 years).Table 1CharacteristicBaselineFollow-up*Demographics*Age at onset (year)60.6 (9.5)--Male sex (%)90 (62.5%)--Education history (year)15.3 (3.0)--Symptoms duration (month)6.5 (6.8)--Positive family history (%)24 (16.9%)--*Clinical Motor Features*UPDRS-Part II5.5 (4.0)10.2 (7.7)UPDRS-Part III20.6 (8.7)27.9 (14.9)Schwab & England score94.6 (5.4)86.2 (13.5)PIGD score0.22 (0.23)0.51 (0.67)*Clinical Non-Motor Features*UPDRS-Part I5.2 (3.7)7.6 (5.5)Epworth sleepiness score5.9 (3.3)8.1 (5.1)Geriatric depression scale (GDS)2.4 (2.6)3.3 (3.6)State-trait anxiety inventory (STAI) score66.6 (18.5)67.8 (22.5)Impulse control disorders (QUIP score)0.28 (0.57)0.33 (0.61)REM sleep behavior disorder (RBD) score3.3 (2.4)4.8 (3.2)SCOPA autonomic score9.1 (6.0)12.7 (6.7)MOCA score27.7 (2.1)26.7 (4.1)

For longitudinal assessments, we defined four major clinical outcomes consisting of:-Motor severity: sum of the severity scores for motor symptoms and signs measured by the MDS-unified Parkinson\'s disease rating scale (MDS-UPDRS) ([@bib0015]) parts II and III, respectively.-Motor phenotype: postural instability gait difficulty (PIGD) score ([@bib0016]).-Cognition: global cognitive status measured by the Montreal cognitive assessment (MoCA) score ([@bib0017]).-Global composite outcome (GCO): for analysis of overall disease progression, we used a previously-published global composite score as a single numeric indicator of prognosis ([@bib0013], [@bib0018]). This was calculated by combining z-scores of: 1) non-motor symptoms (MDS-UPDRS-I), 2) motor symptoms (MDS-UPDRS-II), 3) motor signs (MDS-UPDRS-III), 4) overall activities of daily living (Schwab and England ADL) and 5) global cognition (MoCA score).

2.4. MRI acquisition {#sec0006}
--------------------

We used the initial visit whole-brain T1 structural and diffusion MRI scans of our participants which were performed at various sites on a Siemens 3 Tesla TIM Trio system (Siemens AG, Munich, Germany) using a 12‐channel Matrix head coil. According to the PPMI cohort imaging protocols a three‐dimensional T1 image was acquired using a magnetization‐prepared rapid acquisition gradient echo protocol with the following parameters: repetition time (TR)=2300 ms; echo time (TE)=2.98 ms; field of view (FOV)=256 mm; flip angle=9; and voxel size =1 mm3. The whole‐brain diffusion MRI acquisition sequence used the following parameters: diffusion gradient directions=64; TR=900 ms; TE=88 ms; b‐values=0, 1000s/mm2; FOV=230 × 230 mm; in‐plane resolution=2 mm isotropic; number of contiguous slices=72; slice thickness=2 mm; and acceleration factor=2. Detailed acquisition parameters are available on the PPMI website (<http://www.ppmi-info.org/study-design/research-documents-and-sops/>).

2.5. DTI processing {#sec0007}
-------------------

Diffusion Weighted Imaging data were preprocessed and analyzed using the Oxford Center for Functional MRI of the Brain Diffusion Toolbox (v5.0) (<http://www.fmrib.ox.ac.uk/fsl>) ([@bib0019]). Visual quality assessment was performed after each processing step. Baseline diffusion-weighted scans were first corrected for head motion and eddy currents. Diffusion tensor models were then fitted independently for each voxel within the brain, and FA and MD maps were subsequently computed for each participant.

2.6. Fractional-anisotropy and mean-diffusivity maps {#sec0008}
----------------------------------------------------

Using the previously extracted maps, we mainly focused on six regions of interest (ROI) in the basal ganglia including ventral caudate, dorsal caudate, globus pallidus, nucleus accumbens, ventromedial putamen and dorsolateral putamen and estimated the mean FA and MD in each hemisphere. FA and MD measures were then summed to obtain a whole basal ganglia measure for each hemisphere. Moreover, a previous structural study on the PPMI dataset revealed cortical thinning of various brain regions after 1 year of follow up in PD patients relative to healthy controls ([@bib0020]). Accordingly, we conducted an exploratory analysis on the seven affected cortical regions including bilateral medial and inferior frontal lobe, precentral and postcentral gyri, inferior and medial temporal lobe and left lateral occipital gyri. The results of the cortical analysis are presented in Supplementary material.

2.7. Brain parcellation {#sec0009}
-----------------------

We used the Brainnetome atlas for brain parcellation (<http://www.atlas.brainnetome.org>) ([@bib0021]). This atlas consists of 246 cortical and sub-cortical regions based on MRI-derived structural and functional connectivity patterns and cytoarchitecture. Brainnetome regions were non-linearly transformed into the DTI space of each participant using the FNIRT package of FSL. The affine transformation from a subject\'s native to the structural (T1 MRI) space followed by nonlinear warps/displacement of structural to standard (MNI152) space were calculated and inversely applied on the Brainnetome regions for each participant.

2.8. Network analysis {#sec0010}
---------------------

Interregional white matter tracts were analyzed using a multi-fiber diffusion probabilistic model which estimates probability distribution of one or more connections at each brain voxel using the probtrackx package of FSL ([@bib0022]). Whole brain network construction was performed via tractography between each of the regional labels as a seed and the remaining labels as targets. Using the Brainnetome atlas parcellations, a 246 × 246 weighted interregional connectivity matrix was thus obtained for each participant. Each value within the connectivity matrices represents the number of probabilistic tracts or fiber pathways that connect the two regions. Since diagonal elements represent self-connections, we excluded them from further graph analyses. Thus, the nodes of the graph are the brain parcels and the edges the estimated number of white matter tracts between them.

2.9. Graph theoretical analysis {#sec0011}
-------------------------------

We used the Brain Connectivity Toolbox (<http://www.braim-connectivity-toolbox.net/>) ([@bib0023]) to perform graph theoretical analysis on the individual brain graphs or connectomes. For each connectivity matrix we calculated the following global network measures: 1) global efficiency, the average of the inverse shortest path length; 2) mean clustering coefficient, the mean probability that two nodes connected to an index node are also connected with each other; 3) characteristic path length, the average shortest path length between any two nodes. We also examined the following local characteristics of the graph: 1) nodal degree, the number of connections of any node with the rest of the network; 2) nodal strength, the sum of weights of links connected to a node; 3) clustering coefficient, the fraction of a node\'s neighbors that are neighbors of each other; 4) local efficiency, the efficiency computed on node neighborhoods ([@bib0021]). According to our primary hypothesis, assessments for the local metrics were performed on the 6 distinct basal ganglia sub-regions of each hemisphere based on the Brainnetome atlas parcellations.

2.10. Network-based statistic analysis {#sec0012}
--------------------------------------

Given the fact that the mild motor-predominant and the diffuse-malignant subtypes represent the two extremes of PD clinical severity ([@bib0013]), we used the NBS analysis approach to further identify specific different interregional white matter subnetwork between the two subtypes, using clinical classification from the baseline and follow up visits (4.5 years). By evaluating the null hypothesis at the level of interconnected subnetworks rather than individual connections, we avoided multiple comparisons problems when mass univariate testing is performed at every connection in the graph. Zalesky et al. have provided a detailed description of the NBS methodology ([@bib0010]). Briefly, this method first identifies the supra-threshold connections by using a primary component-forming threshold. Then, the size of the remaining connected components in the network (i.e., number of edges) is determined. Using the null distribution of maximal connected component size obtained empirically by a non-parametric permutation approach, a corrected p-value is calculated. In addition, we re-did this analysis by weighting each connection by fractional anisotropy and mean diffusivity and re-calculated the connectivity matrices across PD subtypes. 5000 permutations were used for this analysis. These results are presented in Supplementary materials.

2.11. Statistical analysis {#sec0013}
--------------------------

We used R v3.2.2 ([@bib0024]) and MATLAB v2108a to perform statistical analysis. We summed the left- and right- hemisphere values of FA and MD as a single aggregate measure. Global and local connectivity metrics were also calculated using the afore-mentioned graph analysis.

One-way ANOVA tests were used to compare differences in baseline DTI measures between various clinical subtypes of PD, defined at baseline and after 4.5 years of follow-up. A two-tailed FDR-corrected p-value \< 0.05 was considered as the significance threshold for the comparative analyses.

Furthermore, we performed an exploratory Pearson correlation analysis to assess whether baseline DTI measures and network metrics associate with longitudinal change in the clinical outcomes of interest after follow-up. Afterwards, we regressed out the effect of age, as a potential confounder, by adjusting all associations for age using partial correlations.

In order to investigate the primary drivers of the relationship between brain measures, demographic features and clinical outcomes in a single model, we performed a partial least square (PLS) analysis ([@bib0025]). PLS is a multivariate approach based on singular value decomposition (SVD) of the data matrices to investigate the linear relationship between two sets of variables. We used the PLS MATLAB toolbox ([@bib0026]) (<https://www.rotman-baycrest.on.ca/index.php?section=84>). This approach was previously explained in detail elsewhere ([@bib0027]). Briefly, SVD was applied to the correlation matrix between two sets of measures (i.e. brain and clinical measures). The significance of the covariance explained for each latent variable was measured using permutation analysis (*N* = 500 repeats). The confidence interval for individual coefficients for each variable loaded in a given latent variable was calculated using bootstrapping (i.e. randomly sampled with replacement, *N* = 500). We ran the analysis with MD- and FA-only to ensure the stability of the results.

2.12. Data availability {#sec0014}
-----------------------

All data used in this manuscript are part of publicly available and de-identified PPMI database (<https://www.ppmi-info.org>). Procedures for data request can be found at <https://www.ppmi-info.org/access-data-specimens/download-data>.

3. Results {#sec0015}
==========

The study population consisted of 90 (62.5%) males and 54 (37.5%) females with an average age of 60.6 (SD=9.5) years and symptom duration of 6.5 (SD=6.8) months at enrollment. Participants were all in the drug-naïve stage with an average MDS-UPDRS-part III score of 20.6 (SD=8.7) and Hoehn and Yahr stage of 1--2 at baseline. Other demographic and clinical measures at baseline and after 4.5 years follow-up are listed in [Table 1](#tbl0001){ref-type="table"}.

3.1. Clinical subtypes of PD {#sec0016}
----------------------------

Using previously determined multi-domain criteria ([@bib0013]), 82 (56.9%) participants were categorized as 'mild motor-predominant', 48 (33.3%) as 'intermediate', and 14 (9.7%) as 'diffuse-malignant' at baseline. Whereas no single microstructural DTI measure in basal nuclei differentiated clinical subtypes at baseline ([Fig. 1](#fig0001){ref-type="fig"}), network metrics significantly varied between the initial subtypes at enrollment ([Fig. 2](#fig0002){ref-type="fig"}). Individuals with 'diffuse-malignant' PD at baseline had significantly lower global efficiency (FDR connected *p* \< 0.05) and higher characteristic path length (FDR corrected *p* \< 0.05, [Fig. 2](#fig0002){ref-type="fig"}, [Table 2a](#tbl0002){ref-type="table"}) compared to the other subtypes.Fig. 1Basal ganglia mean diffusivity in baseline and follow up subtypes of Parkinson\'s disease (PD)(a) Mean diffusivity of basal ganglia sub-regions in baseline (left) and follow up (right) PD sub-types. Diffuse-malignant subtype, particularly after 4.5 years of follow up, showed higher mean diffusivity of nucleus accumbens and globus pallidus. (b) Mean diffusivity of basal ganglia in follow up diffuse-malignant subtype was significantly higher than the mild motor-predominant subtype, (c) Sub-regions of basal ganglia in Brainnetome atlas. MD = mean diffusivity, L = left, R = right, vCa = ventral caudate, GP = globus pallidus, NAC = nucleus accumbens, vmPu = ventromedial putamen, dCa = dorsal caudate, dlPu= dorsolateral putamen, \* = *p*-value \< 0.05.Fig 1Fig. 2Structural brain network and clinical subtypes of Parkinson\'s disease (PD)(a) Global efficiency and characteristic path length showed more disruption in anatomical brain connectivity in diffuse-malignant subtype of PD. (b) Network based statistic identified two subnetworks with decreased efficiency in diffuse malignant compared to mild motor-predominant in the follow up clinical subtypes. The first subnetwork consisted of 6 edges, connecting 7 regions of the brain (corrected *p* \< 0.005) which primarily involved key components of basal ganglia, thalamus and inferior frontal gyrus. The second subnetwork consisted of 5 brain sub-regions including insula and superior temporal gyrus which were connected through 4 edges (corrected *p* \< 0.01). *r* = right hemisphere, IFG = inferior frontal gyrus, BG = basal ganglia, Tha = thalamus, INS = insula, STG = superior temporal gyrus, PoG = post-central gyrus.Fig 2Table 2aBaseline global network measures between distinct clinical subtypes of Parkinson\'s disease, defined at baseline and after 4.5 years of follow-up (*n* = 144).(Values in each cell represent the average z-score of each measure in each subtype).Table 2aParkinson\'s disease clinical subtypes at baseline*Global Network Metrics***Mild Motor-predominantIntermediateDiffuse malignantCorrected *p*-value *~fdr~***Global efficiency0.055270.12158−0.7406**0.033**Characteristic path length−0.0305−0.14540.67711**0.033**Mean clustering coefficient0.042910.01003−0.28570.526Parkinson\'s Disease Clinical Subtypes at Follow-up*Global Network Metrics***Mild Motor-predominantIntermediateDiffuse malignantCorrected *p*-value *~fdr~***Global efficiency0.175316.1E-06−0.9094**\<0.001**Characteristic path length−0.1715−0.03450.98657**\<0.001**Mean clustering coefficient0.050120.01606−0.30520.428

After 4.5 years of follow-up, 62% of patients remained in their subtype, and 38% of the study population switched clinical subtypes. At follow up, 83 (57.6%) were classified as 'mild motor-predominant', 45 (31.3%) as 'intermediate' and 16 (11.1%) as the 'diffuse-malignant' subtype. Differences between local metrics of basal ganglia across PD subtypes are presented in [Table 2b](#tbl0003){ref-type="table"}. As illustrated in [Fig. 1](#fig0001){ref-type="fig"}, mean diffusivity of nucleus accumbens (FDR corrected *p* \< 0.001), globus pallidus (FDR corrected *p* \< 0.05) and the entire basal ganglia (FDR corrected *p* \< 0.05) at the baseline scan could significantly predict clinical subtypes at the 4.5 years of follow-up. Furthermore, participants who were categorized as 'diffuse-malignant' PD after 4.5 years, had significantly lower global efficiency (FDR corrected *p* \< 0.001) and higher characteristic path length (FDR corrected *p* \< 0.001) at baseline ([Table 2a](#tbl0002){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"})Table 2bBaseline local network measures of basal ganglia between distinct clinical subtypes of Parkinson\'s disease, defined at baseline and after 4.5 years of follow-up (*n* = 144).(Values in each cell represent the average z-score of each measure in each subtype).Table 2bParkinson\'s Disease Clinical Subtypes at Baseline*Basal Ganglia***Mild Motor-predominantIntermediateDiffuse malignantCorrected *p*-value *~fdr~***Clustering Coefficient0.074380.04798−0.60.089Nodal Degree0.023610.05079−0.31240.467Nodal Strength−0.00250.16234−0.54190.089Local Efficiency0.074170.06427−0.65480.089Parkinson\'s Disease Clinical Subtypes at Follow-up*Basal Ganglia***Mild Motor-predominantIntermediateDiffuse malignantCorrected *p*-value *~fdr~***Clustering Coefficient0.14702−0.0862−0.52020.076Nodal Degree0.10286−0.0636−0.35480.216Nodal Strength0.10439−0.0192−0.48740.125Local Efficiency0.14992−0.0807−0.55080.076

We also compared nodal metrics of basal ganglia between PD subtypes (Supplementary Fig. e.1). Members of the 'diffuse-malignant' subtype, defined after 4.5 years follow-up, had significantly lower local efficiency of caudate, nucleus accumbens, and dorsolateral putamen at baseline (FDR corrected *p* \< 0.05, Supplementary Fig. e.1). Individuals with 'diffuse-malignant' PD had significantly lower nodal strength in nucleus accumbens (FDR corrected *p* \< 0.05).

Finally, for the cortical regions, at baseline only nodal strength of the pre-central (P*~fdr~*=0.02, mean sum of sub-regional z-scores: mild motor-predominant=0.6871, intermediate=0.8631, diffuse-malignant = −6.9840) and post-central (P*~fdr~*=0.02, mild motor-predominant=0.9431, intermediate= −0.2281, diffuse-malignant = −4.9374) gyri were significantly lower in 'diffuse-malignant' subtype. Moreover, participants who were categorized as 'diffuse-malignant' PD after 4.5 years, had significantly higher mean diffusivity of inferior frontal (P*~fdr~* = 0.042, mild motor-predominant=0.0148, intermediate= 0.0149, diffuse-malignant = 0.0162) and medial (P*~fdr~* = 0.036, mild motor-predominant=0.0081, intermediate= 0.0081, diffuse-malignant = 0.0088) and inferior (P*~fdr~* = 0.018, mild motor-predominant=0.0127, intermediate= −0.0129, diffuse-malignant =0.0136) temporal lobe and lower nodal strength in the seven cortical ROIs (P*~fdr~* \< 0.05).

3.2. Longitudinal progression in clinical outcomes {#sec0017}
--------------------------------------------------

[Table 3](#tbl0004){ref-type="table"} and supplementary table e-1 summarize the results of the exploratory bivariate Pearson and age-adjusted partial correlations between DTI measures at baseline and longitudinal changes in the clinical outcomes of interest after follow-up focusing on the basal ganglia. Baseline mean diffusivity, in all regions, was associated with further increase in PIGD score (faster development of posture and gait problems); however, among basal ganglia nuclei, it remained statistically significant in globus pallidus after regressing out the effect of aging (*r* = 0.25, *p* = 0.003). Baseline mean diffusivity of globus pallidus was also significantly associated with the worsening of motor severity as measured by MDS-UPDRS-parts II-III (*r* = 0.27, *p* = 0.001), cognition as measured by MoCA (*r*=−0.18, *p* = 0.040), and global outcome as shown by the GCO z-score (*r* = 0.30, *p* \< 0.0001) after 4.5 years of follow-up. As shown in [Table 3](#tbl0004){ref-type="table"}, FA failed to demonstrate any significant association with disease progression.Table 3Bivariate Pearson and age-adjusted partial correlations between microstructural/network metrics at baseline and longitudinal changes in the clinical outcomes of Parkinson\'s disease progression after 4.5 years of follow-up.Table 3Imaging MeasuresMotor severityMotor phenotypeCognitionGCO**Δ UPDRS-II-IIIΔ PIGD ScoreΔ MoCA ScoreΔ z-score***Mean Diffusivity*CaudateNS**+0.19 (0.022)**NSNS--NS----PutamenNS**+0.18 (0.031)**NS**+0.19 (0.027)**--NS--NSNucleus AccumbenceNS**+0.21 (0.012)**NSNS--NS----Globus Pallidus**+0.27 (0.001)+0.29 (0.001)−0.18 (0.040)+0.30 (\<0.001)+0.24 (0.004)+0.25 (0.003)**NS**+0.26 (0.003)**Basal GangliaNS**+0.25 (0.002)**NS**+0.21 (0.012)**--**+0.19 (0.026)**--NS*Fractional Anisotropy*CaudateNSNSNSNS--------PutamenNSNSNSNS--------Nucleus AccumbenceNSNSNSNS--------Globus PallidusNSNSNSNS--------Basal GangliaNSNSNSNS--------*Network Metrics*Global EfficiencyNS**−0.30 (\<0.001)+0.22 (0.008)−0.19 (0.026)**--**−0.28 (0.001)+0.21 (0.015)−0.17 (0.052)**Characteristic Path LengthNS**+0.318 (\<0.001)−0.22 (0.009)+0.18 (0.031)**--**+0.30 (\<0.001)−0.20 (0.015)**NSAverage of Clustering CoefficientNSNSNSNS*Nodal Metrics-Basal Ganglia*Clustering CoefficientNS**−0.19 (0.022)+0.21 (0.011)**NS--**−0.20 (0.016)+0.23 (0.006)**--Nodal DegreeNSNSNSNS--**−0.21 (0.015)**----Nodal StrengthNSNS**+0.22 (0.004)**NS----**+0.28 (0.001)**--Local EfficiencyNS**−0.20 (0.014)+0.21 (0.011)**NS--**−0.22 (0.011)+0.23 (0.006)−0.17 (0.045)**[^1]

After running the PLS analysis between MD/FA and the clinical measures, we found that the first latent variable significantly explained the covariance between the two sets of variables ([Fig. 3](#fig0003){ref-type="fig"}). These results showed a relationship between generally higher mean diffusivity in basal ganglia and 1) older age, 2) male gender, 3) more rapid cognitive decline (further reduction in MOCA, 4) more rapid worsening of postural instability and gait (expressed in the PIGD score), and faster progression of global impairment (increased GCO score). The first latent variable accounted for 75% of the covariance. However, these results were mainly driven by the alterations in MD rather than FA, as shown on the previous analysis. In a post hoc analysis we ran PLS analysis separately, for MD and FA. The results were highly stable for MD-only, with a high degree of similarity to the original results, however the first latent variable for FA-only was not significant, indicating a higher contribution of MD to the original covariance explained. Finally, the relationship between MD and clinical measures was consistent and similar in different areas of basal ganglia in the PLS model. This suggests that the alteration in mean diffusivity could be present throughout the whole basal ganglia and not restricted to only one of its sub-components.Fig. 3Relationship between microstructural properties of brain and clinical measures (a) Regional microstructural properties contributing to the first latent variable using partial least square analysis. The confidence intervals calculated using bootstrapping (*N* = 500). (b) Clinical measures contributing microstructural properties to the first latent variable. (c) P-value based on the permutation analysis (*N* = 500), as well as covariance explained for each latent variable. In all plot blue is the main analysis using both mean diffusivity and fractional anisotropy, cyan is for using only mean diffusivity, and green is using only fractional anisotropy (The only mean diffusivity and only fractional anisotropy are only intended as post-hoc analysis for stability of results). L = left, R = right, vCa = ventral caudate, GP = globus pallidus, NAC = nucleus accumbens, vmPu = ventromedial putamen, dCa = dorsal caudate, dlPu = dorsolateral putamen.Fig 3

Investigating the brain network metrics, decreased global efficiency and increased characteristic path length at baseline significantly correlated with increase in GCO (*r*=−0.19 and +0.18 respectively, *p* ≤ 0.05), increase in PIGD scores (*r*=−0.30 and +0.32 respectively, *p* \< 0.001) and decline in MoCA (*r*=+0.22 and −0.22 respectively, *p* \< 0.05) after follow-up. These associations remained statistically significant after regressing out the effect of aging ([Table 3](#tbl0004){ref-type="table"}). In basal ganglia network, higher clustering coefficient and local efficiency at baseline correlated with less increase in PIGD score (*r*=−0.19 and −0.20, *p* \< 0.05) and less decline in MoCA score (*r* = 0.21 and 0.21, *p* \< 0.05) after 4.5 years. Participants with higher nodal strength of basal ganglia also experienced less cognitive decline after follow-up (*r* = 0.25, *p* = 0.003). The associations between baseline nodal metrics in basal ganglia and longitudinal change in MoCA and PIGD scores were independent of the effect of aging ([Table 3](#tbl0004){ref-type="table"}).

We also explored how nodal metrics in each sub-region of the basal ganglia associated with the progression of clinical outcomes (Table e-1). Region-specific nodal metrics were mostly associated with the change in PIGD score and cognitive status. Among basal ganglia sub-regions, nodal metrics of dorsolateral putamen significantly correlated with worsening of all clinical measures, namely motor severity, gait and postural instability, cognitive status and the GCO. Nodal metrics of nucleus accumbens also significantly associated with longitudinal change in motor phenotype as measured by PIGD score and cognitive impairment after 4.5 years (Table e-1).

Studying the cortical ROIs, only mean diffusivity of inferior temporal lobe showed significant correlation with PIGD (P*~fdr~* = 0.006, *r* = +0.302), MOCA (P*~fdr~* = 0.01, *r* = −0.27) and GCO (P*~fdr~* = 0.009, *r* = 0.323) scores. Network measurements revealed no correlation with clinical measures after correcting for multiple comparisons.

3.3. Whole brain mapping of PD subtypes {#sec0018}
---------------------------------------

NBS detected two subnetworks of significantly reduced connectivity at the baseline connectomes, in patients who were later subtyped as 'diffuse-malignant' compared to the 'mild-motor predominant' patients by the 4.5 years follow up classification (*p* \< 0.05, corrected for multiple comparisons; [Fig. 2](#fig0002){ref-type="fig"}). The first subnetwork consisted of 6 edges, connecting 7 regions of the brain (corrected *p* \< 0.005) which primarily involved key components of regions known to be involved in PD like basal ganglia, thalamus and inferior frontal gyrus sub-regions. The second significantly different subnetwork consisted of 5 brain regions including insula and superior temporal gyrus sub-regions of the barainnetome parcellation which were connected through 4 edges ([Table 4](#tbl0005){ref-type="table"}). On the other hand, the FA-weighted connectivity matrices revealed no difference across a wide range of thresholds between the diffuse-malignant and mild motor-predominant subtypes of PD, defined at baseline and after 4.5 years. However, the MD-weighted connectome demonstrated three sub-networks with higher mean diffusivity in diffuse-malignant subtype of PD defined after 4.5 years of follow up compared to mild motor-predominant subtype. Similarly, basal ganglia, insula, cingulate and pre and post-central gyri were notably involved in different sub-networks of the MD-weighted matrices (Supplementary material).Table 4Networks identified to be significantly different between the "diffuse-malignant" and "mild-motor predominant" subtypes of Parkinson\'s disease, based on the 4.5-years follow up classification by using the Network-Based Statistical analysis.Table 4Networks and connections*t* value*Network 1 (7 nodes, 6 edges, p* = *0.003)*Right inferior frontal gyrus, caudal area 45 and Right globus pallidus*t* = 3.03Right Inferior frontal gyrus, caudal area 45 and Right dorsolateral putamen*t* = 2.94Right Inferior frontal gyrus, rostral area 45 and Right medial pre-frontal thalamus*t* = 2.97Right Inferior frontal gyrus, rostral area 45 and Right pre-motor thalamus*t* = 3.23Right Inferior frontal gyrus, caudal area 45 and Right lateral pre-frontal thalamus*t* = 3.01Right Inferior frontal gyrus, rostral area 45 and Right lateral pre-frontal thalamus*t* = 2.90*Network 2 (5 nodes, 4 edges, p* = *0.009)*Right superior temporal gyrus TE1.0-TE1.2 and Right superior temporal gyrus, caudal area 22*t* = 3.72Right superior temporal gyrus TE1.0-TE1.2 and Right dorsal granular insula*t* = 3.46Right post-central gyrus and Right dorsal dys-granular insula*t* = 3.13Right dorsal granular insula and Right dorsal dys-granular insula*t* = 3.61

4. Discussion {#sec0019}
=============

Having explored a large DTI set of early-phase, drug-naïve PD patients, our study provided new evidence that these measures of structural neural disruption can predict clinical motor and non-motor outcomes of PD. In this longitudinal cohort, we analyzed microstructural damage of regional integrity (reflected by increased diffusivity) and disruption of the brain\'s connectivity pattern predicted progression of motor and non-motor symptoms over time. The fact that baseline DTI properties could identify clinically distinct sub-types of PD patients after 4.5 years of follow up, highlights a key role for DTI biomarkers in classifying and predicting PD prognosis over time.

4.1. Microstructural abnormalities and PD progression {#sec0020}
-----------------------------------------------------

Disruption in coherence of the underlying brain tissue is mainly reflected by a decrease in FA or an increase in MD. Although for most of the brain regions decreased FA and increased MD occur together in a similar pattern, in some regions one measure dominates, as FA is more sensitive to tissue directionality, while MD mainly represents tissue density and extracellular fluid accumulation ([@bib0028]). Disruption of the white matter integrity occurs in PD across several regions of the cerebral white matter and is particularly notable in subcortical areas ([@bib0002], [@bib0004], [@bib0029], [@bib0030]). Focusing on the basal ganglia and in line with pathologic pattern of PD development, we found significant associations between increased mean diffusivity of the basal ganglia sub-regions (particularly globus pallidus) at the very early de novo stage, and progression of global composite outcome after 4.5 years of follow up. The baseline MD value of globus pallidus also positively correlated with motor and cognitive progression and faster development of gait problems as measured by PIGD scoring. We did not find the same association for FA, a finding that was largely replicated by the PLS analysis. Several studies reported positive correlation between DTI measures of nigrostriatal projection loss and motor severity in PD ([@bib0008], [@bib0031], [@bib0032]); however, other studies did not replicate the association ([@bib0033], [@bib0034]). Zhang et al. reported higher rates of FA reduction and radial and axial diffusivity increases predominately in substantia nigra, midbrain and thalamus of PD patients in the same cohort (PPMI), after one year of follow up, compared to normal aging. They also observed that a steep increase in diffusivity of thalamus correlated with fast cognitive decline measured by MoCA; however, they found no significant correlation between microstructural DTI changes and UPDRS score after one year ([@bib0005]). Previous studies on PD showed that cognitive impairment in executive and visuospatial domains associated with increases in diffusivity of thalamic ([@bib0035]), prefrontal ([@bib0036]) and frontal ([@bib0037]) regions. Zheng et al. reported that MD of various subcortical regions associated more strongly with performance in distinct cognitive domains than FA ([@bib0038]). In addition, MD in putamen was positively correlated with MDS-UPDRS motor score ([@bib0039]) as well as MDS-UPDRS motor progression over 6 years ([@bib0012]). PD patients with freezing of gait showed higher MD values in subcortical structures such as basal ganglia compared to patients without gait freezing ([@bib0040]). It is interesting to note that the highest correlation of DTI changes with PD progression over 4.5-years of follow up was found for globus pallidus, which has a primary action in movement regulation and is used as a target for deep brain stimulation in PD ([@bib0041]). This is in line with previous results which showed a significant increase in diffusivity of the globus pallidus in PD patients compared to healthy controls ([@bib0029], [@bib0042]) and its correlation with motor severity in the PIGD subtype of PD ([@bib0043]).

In general, disruption of motor and cognitive function in PD may be related to more severe loss of brain tissue as reflected by diffusivity, than by disruption in tissue coherence ([@bib0038], [@bib0039]). Taken together, our results may suggest that baseline microstructural alterations of the brain regions, measured by increased diffusivity are not only correlated with major symptoms of PD ([@bib0044]) but also predict long term motor and non-motor outcomes of PD.

4.2. Structural network properties and PD progression {#sec0021}
-----------------------------------------------------

Implementing graph theoretical analysis, our results revealed significant correlations between baseline structural brain networks and future clinical outcomes of PD. Several studies have previously noted disruption of anatomical brain networks in PD patients compared to healthy controls ([@bib0011], [@bib0045]). More specifically, PD patients have demonstrated decreased efficiency of various global and local metrics of structural connections. In PPMI, PD patients have been shown to have disrupted structural connectivity at the global level compared to healthy controls ([@bib0009]). Few connectomic analyses have also investigated the correlation between altered brain networks and clinical manifestations in PD and reported that impaired cognition is associated with disruption of functional and structural brain networks ([@bib0046], [@bib0047]). Similar studies could not replicate such associations for severity of motor symptoms ([@bib0011], [@bib0048], [@bib0049]), resulting in general lack of consensus on the association of brain networks and clinical manifestations in PD. In the current longitudinal study, however, we observed remarkable links between baseline structural network metrics and clinical features of PD, both at the early drug-naïve stage and after 4.5 years of follow-up. Decreased global efficiency and increased characteristic path length which reflect disruption in the integration of brain connections were correlated with worsening of PIGD, MoCA and GCO scores after 4.5 years of follow up. Considering the key role of basal ganglia in PD, we observed that disruption of the local network metrics including clustering coefficient, local efficiency, nodal strength and degree in basal ganglia components, substantially correlated with progression of various motor and non-motor symptoms. These findings suggest that damages of structural connectivity pattern, either globally or locally in basal ganglia sub-regions, contribute to various clinical manifestations of PD. In other words, we found that similar to other neurodegenerative disorders ([@bib0050], [@bib0051]), structural connectivity pattern of the brain alters in early stages of PD and is correlated with clinical progression of the disease over time, as reflected in our graph theoretical analyses.

4.3. DTI and clinical subtypes of PD {#sec0022}
------------------------------------

Our results showed that DTI properties could significantly discriminate PD patients with different clinical subtypes after 4.5 years of follow up. Patients in the 'diffuse-malignant' subtype at baseline had increased diffusivity of basal ganglia and more disruption in global and local connectivity patterns, relative to the other subtypes. Indeed, clinical manifestations of PD directly associated with a distinct pattern of DTI properties. In general, microstructural and connectomic analyses followed a disruptive trend as clinical symptoms were more severe from 'mild-motor predominant' to 'diffuse-malignant' subtype (Supplementary Fig. e.1).

In addition, our NBS analyses demonstrated a distinct brain network characterizing the structural connectivity abnormalities in the 'diffuse-malignant' subtype compared to 'mild motor-predominant' PD. The involved anatomical regions were predominantly pathways related to basal ganglia, thalamus and insula which is relatively consistent with spread of PD neurodegeneration.

The challenge of great heterogeneity in clinical manifestations of PD is largely illuminated by demonstrating differences in microstructural, graph theoretical and NBS analyses of DTI measures between distinct PD subtypes. These findings also provide additional validity for multi-domain classification of PD. Nevertheless, the fact that baseline DTI measures and network metrics were more prominently different between subtypes that were defined after 4.5 years follow-up clinical evaluations than those defined at baseline, highlights the potential of imaging biomarkers data to further optimize subtyping in PD.

4.4. Limitations and strengths {#sec0023}
------------------------------

This study has several limitations. Our study was restricted to PPMI subjects and 3T imaging, so DTI studies with different protocols or imaging acquisition of higher fields may reveal additional details. Some technical limitations are inherent in multi-center studies, which PPMI has minimized by setting guidelines for data gathering. Another potential limitation is the choice of region of interest; additional group differences may be observable with analysis of other brain regions.

On the other hand, the current study has several strengths. We were able to study a large sample size of de novo PD patients enrolled at PPMI centers across the world which enhances generalizability of our findings. Also, here we have investigated basal ganglia sub-regions in detail by employing the Brainnetome atlas, which allowed us to clarify the contributions of particular sub-regions in pathophysiology of PD manifestations. Furthermore, we applied PLS as an innovative approach and the findings were consistent with our primary analyses, demonstrating a low possibility for multiple comparison bias. Finally, to the best of our knowledge, this is the first study that investigated the relationship between comprehensively-defined PD outcomes and different PD phenotypes to DTI MRI properties, on a large sample of PD patients over time.
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[^1]: In each cell, data are presented as correlation coefficient (p-value) followed by age-adjusted values in the second row. Data on fractional anisotropy and mean diffusivity sections are incorporated as sum of the left- and right-side values. Correlations that remained statistically significant are bolded. GCO = Global Composite Outcome, UPDRS = Unified Parkinson\'s disease Rating Scale, MoCA = Montreal Cognitive Assessment, **Δ =** change in the clinical outcome, NS = not significant.
